---
provider: claude_code
model: claude-haiku-5-5, claude-opus-5-5
cached: false
start_time: '2026-11-09T19:47:19.308392'
end_time: '2026-11-09T19:51:12.301815'
duration_seconds: 232.99
template_file: templates/disease_pathophysiology_research.md
template_sha: "f452f0a9c7e3536175154b9683c45663f686f283"
template_variables:
  disease_name: Desbuquois Dysplasia 1
  mondo_id: MONDO:0009629
  category: Mendelian
  causal_genes: CANT1
  omim_id: OMIM:251450
  synonyms: Desbuquois dysplasia type 1; CANT1 Desbuquois dysplasia; Desbuquois dysplasia
    caused by mutation in CANT1
provider_config:
  timeout: 1800
  max_retries: 3
  parameters:
    allowed_domains: []
    claude_executable: claude
    skip_permissions: false
    allowed_tools:
    - WebSearch
    - WebFetch
    add_dirs: []
    timeout: 1800
    min_report_chars: 200
    extra_args: []
run_metadata:
  models_used:
  - claude-haiku-5-5
  - claude-opus-5-5
  web_search_requests: 3
  num_turns: 18
  total_cost_usd: 2.0130473999999996
  session_id: f7f93090-5a85-4467-8657-ba04b92d71dc
  stop_reason: end_turn
  permission_denials: 2
  denied_tools:
  - Bash
  assistant_text_blocks: 2
citation_count: 9
reference_validation:
  total_references: 26
  verified: 26
  not_found: 0
  unverifiable: 0
  confabulation_rate: 0.0
  quotes_checked: 2
  quotes_valid: 2
  relevance_assessed: 26
  on_topic: 20
  validator_version: 0.5.1
term_validation:
  total_terms: 71
  verified: 67
  not_found: 1
  obsolete: 1
  unverifiable: 2
  confabulation_rate: 0.014
  labels_checked: 9
  labels_matching: 4
  labels_mismatched: 1
  mislabelled_terms:
  - term_id: UBERON:0003672
    reported_labels:
    - verify
    ontology_label: dentition
  labels_variant: 4
  unresolved_terms:
  - HP:0009619
  obsolete_terms:
  - term_id: GO:0030206
    ontology_label: obsolete chondroitin sulfate biosynthetic process
    replaced_by: GO:0050650
  unresolvable_prefixes:
  - OMIM
  - ORPHA
  needs_review: true
  adapter: 'ols:'
  validator_version: 0.4.5
---

## Question

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** Desbuquois Dysplasia 1
- **MONDO ID:** MONDO:0009629 (if available)
- **Causal gene(s):** CANT1
- **OMIM:** OMIM:251450
- **Synonyms:** Desbuquois dysplasia type 1; CANT1 Desbuquois dysplasia; Desbuquois dysplasia caused by mutation in CANT1
- **Category:** Mendelian

Many disease names are serial numbers ("... autosomal dominant 64", "... 26") that
do not say which gene the disease is about, and a similarly named disease with a
different gene is easy to research by mistake. Research the disease with the MONDO
ID and causal gene given above, and name its causal gene in your first paragraph.
If the name seems to point to a different gene or OMIM entry, follow the
identifiers above.

## Research Objectives

Please provide a comprehensive research report on **Desbuquois Dysplasia 1** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

**Present this section as an ordered causal chain first, then the detail below.**
Open with a numbered sequence of mechanistic steps running from the initiating
lesion (mutation, exposure, infection) to the clinical manifestation, one step per
line, each naming what it causes next. State the causal verb explicitly ("leads
to", "results in") and say where a step is inferred rather than demonstrated.
Where the mechanism branches, show the branch. The categories below are a
checklist of what to cover within those steps, not the organizing structure —
a step may draw on several of them, and a category may contribute to several
steps.

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


## Output

Searching PubMed via WebFetch to pin down PMIDs for the CANT1 literature.

I have enough sources now and am writing the report.

# Desbuquois Dysplasia 1 (DBQD1; CANT1): Research Report

**Target:** Desbuquois dysplasia 1, MONDO:0009629, OMIM:251450. **Causal gene:** *CANT1* (calcium-activated nucleotidase 1, hgnc:19721, chromosome 17q25.3). This report covers the CANT1 form only. Desbuquois dysplasia 2 (MONDO:0014343) is caused by *XYLT1* and is out of scope, except where the two forms are compared.

**About the sources.** Quotes come from PubMed abstracts fetched through NCBI E-utilities during this session. The fetch tool shortened some of them, and its notes say it joined line breaks with single spaces. Before any quote becomes a KB `snippet`, it must be checked against the cached abstract (`just fetch-reference PMID:…`). Identifiers I could not confirm (the Orphanet code, ICD codes, MeSH) are marked as unverified.

---

## 1. Disease information

**Overview.** Desbuquois dysplasia (DBQD) is an autosomal recessive osteochondrodysplasia in the multiple-dislocation group. Its main features are:
- severe short stature that starts before birth and gives rhizomelic or mesomelic shortening;
- marked joint laxity with multiple dislocations;
- a round, flat face with a flat nasal bridge, prominent eyes and micrognathia (sometimes cleft palate);
- typical radiographs: a "Swedish-key" or "monkey-wrench" proximal femur, with a short femoral neck and an exaggerated lesser trochanter, and advanced carpal and tarsal bone age.

**Type 1 versus type 2.** The two types were originally told apart by the hands:
- **Type 1:** an accessory ossification centre distal to the second metacarpal, a bifid distal thumb phalanx, or a delta phalanx, with other changes.
- **Type 2:** normal hands.
- **Kim variant:** short metacarpals with elongated phalanges.

Molecular studies showed that this hand-based split does not map cleanly onto genes. *CANT1* mutations are found in all type 1 cases, in the Kim variant, and in some type 2 cases (Nizon 2012, PMID:22539336; Furuichi 2011, PMID:21037275).

**Identifiers**

| Resource | ID | Status |
|---|---|---|
| MONDO | MONDO:0009629 "Desbuquois dysplasia 1"; parent MONDO:0015426 "Desbuquois dysplasia" | confirmed in repo `cache/mondo/terms.csv` |
| OMIM | 251450 (DBQD1); gene *CANT1* 613165 | from template; gene MIM from memory, verify |
| HGNC | hgnc:19721 CANT1 | confirmed (repo ClinGen cache) |
| ClinGen | CANT1 / DBQD1, AR, **Definitive**, Prenatal GCEP, 2024-11-20, `CGGV:assertion_30c64852-60e0-44ce-bf10-cf7af11b1fa9-2024-11-20T170000.000Z` | confirmed (`cache/clingen/gene_validity.csv`) |
| Orphanet | ORPHA:1425 (Desbuquois dysplasia) | **unverified**: Orphanet page blocked by bot check; `references_cache` holds no ORPHA file |
| ICD-10 / ICD-11 | Q77.x / LD24.x (osteochondrodysplasias) | **unverified**: do not bind without lookup |
| MedGen | C4012146 | from search result |

**Synonyms:** Desbuquois dysplasia type 1; DBQD1; CANT1-related Desbuquois dysplasia. Older umbrella names are Desbuquois syndrome and micromelic dwarfism with vertebral and metaphyseal abnormalities and advanced carpotarsal ossification.

**What the evidence is based on:** case reports, family series and one systematic review of published cases (Piwar 2024, 111 cases). There are no EHR cohorts or registries.

## 2. Etiology

- **Cause:** biallelic (homozygous or compound heterozygous) loss-of-function variants in *CANT1*.
  - Huber 2009 (PMID:19853239): "Studying nine Desbuquois families, we identified seven distinct mutations in the" *CANT1* gene. Four were nonsense or frameshift variants and three were missense ("p.R300C, p.R300H, and p.P299L").
  - Furuichi 2011 (PMID:21037275): "the missense mutations were all associated with loss-of-function."
- **Genetic risk factors:**
  - Parental consanguinity is the main risk factor: "approximately 60% of patients had a history of parental consanguinity" (Piwar 2024, PMID:39273648).
  - There are founder alleles in East Asia (c.676G>A p.Val226Met) and in a German cluster (c.228_229insC).
- **Environmental risk factors, protective factors and gene–environment interactions:** none known. The disease is fully genetic.
- **Modifier genes:** none reported.

## 3. Phenotypes

Onset is prenatal or congenital for all core features. Severity varies, from lethal fetal hydrops to survival into adulthood. Frequencies are given only where a source states them; otherwise they are described qualitatively.

| Phenotype | Suggested HPO | Notes / frequency | Key source |
|---|---|---|---|
| Severe prenatal-onset short stature / growth restriction | HP:0003561 Birth length less than 3rd percentile; HP:0001511 IUGR; HP:0004322 Short stature | Core (very frequent) | Faden 2010 PMID:20425819 "severe growth restriction and distinct hand and proximal femur appearance" |
| Rhizomelic/mesomelic limb shortening | HP:0008905 Rhizomelia; HP:0009826 Limb undergrowth | Core | Thomas 2021 PMID:34602954 "short limbs" |
| Generalized joint laxity | HP:0001382 Joint hypermobility | Core | Singh 2015 PMID:25486376 |
| Multiple joint dislocations (hips, knees, elbows) | HP:0002999 Patellar dislocation; HP:0002827 Hip dislocation; HP:0001373 Joint dislocation | Core | Singh 2015 "laxity, dislocation of multiple joints"; Biji 2023 PMID:36331722 |
| Accessory ossification centre distal to MC2; bifid/delta phalanx of thumb | HP:0006149 (accessory carpal/phalangeal ossification centers — **verify**); HP:0009619 Bifid distal phalanx of thumb (verify) | **Defines type 1**; absent in Kim variant | Nizon 2012 |
| Short metacarpals with elongated phalanges | HP:0010049 Short metacarpal | Kim variant | Furuichi 2011; Singh 2015 |
| "Monkey-wrench" proximal femur, prominent lesser trochanter | HP:0003367 Abnormality of femoral neck (verify specific term) | Hallmark radiographic sign | Faden 2010 |
| Advanced carpal/tarsal ossification | HP:0001156 Brachydactyly + HP:0004232 Accessory carpal bones / HP:0010880 advanced bone age (verify) | Characteristic | review literature |
| Round flat face, flat nasal bridge, prominent eyes, micrognathia | HP:0000311 Round face; HP:0005280 Depressed nasal bridge; HP:0000520 Proptosis; HP:0000347 Micrognathia | Frequent | Thomas 2021 "distinctive facies" |
| Cleft palate | HP:0000175 | Occasional | — |
| Kyphoscoliosis / thoracic kyphosis | HP:0002751 Kyphoscoliosis | Progressive | Kodama 2020 (mouse) |
| Respiratory distress, narrow thorax / pulmonary hypoplasia | HP:0002097 Emphysema? no — use HP:0002093 Respiratory insufficiency; HP:0002089 Pulmonary hypoplasia | Main cause of early death | Thomas 2021; Laccone 2011 PMID:21654728 "lung hypoplasia" |
| Fetal hydrops | HP:0001789 Hydrops fetalis | Lethal end of spectrum | Laccone 2011 "three hydropic fetuses of 17, 22 and 25 gestational weeks" |
| Mitral valve prolapse | HP:0001634 | 7/9 (77%) | Öztürk 2025 PMID:40461715 |
| Aortic root enlargement | HP:0002616 Aortic root aneurysm / HP:0004942 | 6/9 (66%), can progress | Öztürk 2025 |
| Atrial septal defect (small) | HP:0001631 | 5/9 (55%) | Öztürk 2025 |
| Hypospadias, hypoplastic scrotum | HP:0000047; HP:0000046 | Reported once | Thomas 2021 |
| Developmental delay (usually motor, secondary to joint problems) | HP:0001263 | Variable | Singh 2015 |
| Multiple epiphyseal dysplasia-like presentation (mild end) | HP:0002654 | Specific allele p.Trp125Cys | Daşar 2025 PMID:39618316 |

**Quality of life.** I found no EQ-5D or SF-36 data. The main burdens are joint instability and dislocations (mobility), progressive spinal deformity, respiratory compromise in infancy, and newly recognised aortopathy.

## 4. Genetic and molecular information

**Gene:** *CANT1*, hgnc:19721. Its product is a Golgi/ER-resident, type II transmembrane, calcium-dependent nucleotidase that preferentially hydrolyses UDP to UMP and phosphate (UniProt Q8WVQ1; verify).

**Variant spectrum.** Variants include nonsense, frameshift, splice/intronic and missense changes; missense variants cluster in conserved nucleotidase regions. Piwar 2024: "over 35% of cases involving missense mutations, primarily affecting the CANT1 gene."

| Variant | Type | Notes | Source |
|---|---|---|---|
| c.898C>T p.Arg300Cys; p.Arg300His | missense | R300 hotspot, 5/9 families in the first series | Huber 2009; Thomas 2021 (NM_138793.4) |
| c.896C>T p.Pro299Leu | missense | recurrent | Huber 2009; Biji 2023 |
| c.676G>A p.Val226Met | missense | **East Asian founder** (Japanese/Korean), haplotype up to 550 kb; common in Kim variant | Dai 2011 PMID:21412251 |
| c.228_229insC | frameshift | German founder, hydrops | Laccone 2011 |
| c.277_278delCT p.Leu93ValfsTer89 | frameshift | | Laccone 2011; Thomas 2021 |
| c.336C>A p.Asp112Glu | missense | hydrops | Laccone 2011 |
| c.467C>T p.Ser156Phe | missense | Indian Kim variant | Singh 2015 |
| c.594G>A p.Trp198*; c.734C>T p.Pro245Leu | nonsense / missense | Pro245Leu abolishes dimerization; both reduce activity | Wang 2020 PMID:32907608 |
| c.902_906dup p.Ser303fs*20 | frameshift | antenatal lethal | Biji 2023 |
| c.375G>C p.Trp125Cys | missense | MED-like milder phenotype | Daşar 2025 |
| 5-bp duplication | frameshift | | Faden 2010 |

- **Classification:** most variants are listed in ClinVar as pathogenic or likely pathogenic (not checked individually). At the gene level, ClinGen rates CANT1 **Definitive** for this disease.
- **Population frequency:** pathogenic alleles are rare in gnomAD. No carrier-frequency estimate has been published.
- **Origin and mechanism:** all variants are germline. The functional consequence is **loss of function**: missense variants reduce nucleotidase activity (Furuichi 2011; Wang 2020). Wang 2020 also shows loss of dimerization and secretion ("The CANT1 dimer of mut2 was significantly reduced and even undetectable"). A dominant-negative effect has been proposed for some R300 alleles, but I found no abstract-level evidence for it, so treat it as unconfirmed.
- **Genotype–phenotype:** variant type broadly tracks severity. Thomas 2021 ascribed different severity grades to variant type, and truncating variants are over-represented among the hydropic and lethal cases.
- **Epigenetic changes and chromosomal abnormalities:** none reported.

## 5. Environmental information

Not applicable. No environmental, lifestyle or infectious factors are known.

## 6. Mechanism and pathophysiology

**Ordered causal chain**

1. Biallelic loss-of-function *CANT1* variants **lead to** absent or inactive CANT1 nucleotidase in the ER and Golgi. Loss of dimerization, secretion and activity is shown in vitro (Wang 2020; Furuichi 2011).
2. Loss of Golgi UDP-to-UMP hydrolysis **is thought to result in** UDP building up in the Golgi lumen and less UMP being available for exchange through nucleotide-sugar antiporters. This would reduce the supply of UDP-sugars (UDP-xylose, UDP-GlcA, UDP-GalNAc) and possibly product-inhibit glycosyltransferases. *This step is inferred from enzyme function and has not been measured directly in patient tissue.*
3. That **results in** impaired glycosaminoglycan (GAG) chain synthesis on proteoglycans.
   - Patient fibroblasts: "significant reduced GAG synthesis in presence of β-D-xyloside" (Nizon 2012).
   - Mouse chondrocytes: "the glycosaminoglycan synthesis was decreased in chondrocytes from Cant1 knock-out mice" (Paganini 2019, PMID:30439444).
4. The resulting proteoglycans (aggrecan, decorin) carry **shorter GAG chains** with **increased sulfation**, and their **secretion is delayed**.
   - Paganini 2019: "whilst the sulfation was increased and the overall proteoglycan secretion was delayed."
   - Gramegna Tota 2024, PMID:39334831: "proteoglycans with shorter GAG chains compared with wild-type animals."
   - **Branch, cellular stress:** chondrocytes show "dilated ER cisternae" but "no canonical ER stress response was detected" (Paganini 2019).
5. The growth-plate extracellular matrix becomes depleted of GAG and matrix space shrinks. This **leads to** deregulated chondrocyte proliferation and **impaired terminal hypertrophic differentiation** (Kodama 2020, PMID:32277574: "terminal differentiation to hypertrophic chondrocytes, was impaired in Cant1 KO mice").
6. Defective endochondral ossification **results in** prenatal-onset short stature, limb shortening, narrow thorax with pulmonary hypoplasia, and typical femoral and hand malformations.
7. **Branch, connective tissue:** the same proteoglycan defect in ligament, tendon and skin (decorin with short dermatan/chondroitin sulfate chains, abnormal collagen fibrillogenesis; Yamashita 2025, PMID:40141107) **is thought to lead to** joint laxity and multiple dislocations. The extension to joint laxity is inferred from mouse tendon data.
8. **Branch, cardiovascular (inferred):** a matrix proteoglycan defect in valves and aortic wall **may underlie** mitral valve prolapse and aortic root dilatation (Öztürk 2025). This link is proposed, not demonstrated.

**Suggested GO terms (verify each with a lookup)**

| Mechanism | Suggested GO term |
|---|---|
| CANT1 activity | GO:0045134 UDP phosphatase activity; nucleoside diphosphate phosphatase activity (GO:0017110) |
| GAG chain synthesis | GO:0006024 glycosaminoglycan biosynthetic process; GO:0030206 chondroitin sulfate biosynthetic process; GO:0030166 proteoglycan biosynthetic process |
| Delayed proteoglycan secretion | GO:0009306 protein secretion |
| Growth-plate defect | GO:0002063 chondrocyte development; GO:0003418 growth plate cartilage chondrocyte differentiation; GO:0003413 chondrocyte differentiation involved in endochondral bone morphogenesis; GO:0001958 endochondral ossification |
| Tendon/collagen defect | GO:0030199 collagen fibril organization |

**Cell types (CL):** CL:0000138 chondrocyte; CL:0000743 hypertrophic chondrocyte; CL:0000057 fibroblast; CL:0000388 tendon cell.

**Small molecules (CHEBI, verify):** UDP; UMP; chondroitin sulfate; dermatan sulfate.

**Cellular components (GO CC):** GO:0005794 Golgi apparatus; GO:0005783 endoplasmic reticulum.

**Omics, single-cell and functional screens:** a microarray of knockout chondrocytes was reported in Paganini 2019. No other omics, single-cell or CRISPR-screen data were found.

**Mechanistic family:** DBQD2 (*XYLT1*) and other GAG-linkage disorders (*CHST3*, *B3GAT3*, *IMPAD1*, *SLC26A2*) share the proteoglycan-biosynthesis mechanism (Tsujioka 2026 review, PMID:42094029).

## 7. Anatomical structures affected

- **Primary:**
  - skeleton, especially growth-plate cartilage (UBERON:0002418 cartilage tissue; growth plate UBERON:0003672 — verify);
  - long bones and proximal femur (UBERON:0000981 femur);
  - hand (UBERON:0002398 manus), including metacarpals and phalanges;
  - spine;
  - joints and ligaments (UBERON:0000211 ligament);
  - tendon (UBERON:0000043).
- **Secondary:**
  - lungs (pulmonary hypoplasia, UBERON:0002048);
  - heart valves (mitral valve UBERON:0002135);
  - aortic root (UBERON:0001496 ascending aorta — verify);
  - palate;
  - external genitalia (one report).
- **Laterality:** findings are bilateral and symmetric.

## 8. Temporal development

- **Onset:** prenatal. Short limbs and hydrops are detectable on second-trimester ultrasound, at 17–25 weeks in the Laccone 2011 series.
- **Course:**
  - Neonatal and infant period: the highest risk is respiratory insufficiency.
  - In survivors: dislocations persist and kyphoscoliosis progresses through childhood.
  - Aortopathy can begin early and progress, over a median 7.7-year follow-up (Öztürk 2025).
- **Duration:** lifelong. There is no remission.
- **Critical periods:** the perinatal period for airway and respiration; childhood for orthopaedic management of dislocations and spinal deformity.

## 9. Inheritance and population

- **Inheritance:** autosomal recessive (HP:0000007), with complete penetrance and variable expressivity, from lethal hydrops to an MED-like presentation. No anticipation is known.
- **Consanguinity:** about 60% of published cases (Piwar 2024).
- **Founder effects:**
  - c.676G>A in Japanese and Korean patients: "should be derived from a common founder" (Dai 2011);
  - c.228_229insC in Germany (Laccone 2011).
- **Prevalence:** unknown. Orphanet lists DBQD as <1/1,000,000 (unverified). Piwar 2024 counted 111 published cases across all forms, of which 54 were DBQD1, 39 DBQD2 and 14 Kim variant.
- **Geography:** reported worldwide, including Europe, the Middle East (Saudi Arabia, Egypt, Turkey), South Asia, East Asia and Thailand.
- **Sex ratio:** about 1:1, as expected for an autosomal recessive disease.

## 10. Diagnostics

- **Imaging:** prenatal ultrasound (short long bones, hydrops, narrow thorax) and a postnatal skeletal survey. The key signs are the monkey-wrench femur, hand accessory ossification centres, advanced carpal age and dislocations.
- **Genetic testing:**
  - *CANT1* sequencing, or a skeletal-dysplasia panel (*CANT1*, *XYLT1*, *CHST3*, *B3GAT3*, *FLNB*, *SLC26A2* and others).
  - Exome sequencing for antenatal lethal presentations (Biji 2023).
  - SNP-array homozygosity mapping helps in consanguineous families (Forster 2019, PMID:31587486).
  - CMA, karyotype, FISH, mtDNA and repeat testing are not relevant.
- **Functional assays (research only):** nucleotidase activity on expressed mutants; GAG synthesis in fibroblasts.
- **Biomarkers:** none in clinical use.
- **Differential diagnosis:**
  - DBQD2 (*XYLT1*): normal hands, CANT1 negative;
  - Larsen syndrome (*FLNB*);
  - CHST3-related spondyloepiphyseal dysplasia with dislocations;
  - B3GAT3-related multiple-joint-dislocation disorders;
  - pseudodiastrophic dysplasia;
  - Ehlers-Danlos syndromes;
  - multiple epiphyseal dysplasia, at the mild end.
- **Screening:** no newborn screening. Carrier and cascade testing applies in families with a known variant, and prenatal or preimplantation diagnosis is available (Özalp 2025, PMID:40368527; Kuang 2020, PMID:32922611).

## 11. Outcome and prognosis

- **Mortality:** high perinatal and infant mortality from respiratory insufficiency and pulmonary hypoplasia; hydropic fetuses do not survive (Laccone 2011; Thomas 2021 "respiratory distress"). No survival rates have been published.
- **Long-term problems in survivors:** severe short stature, recurrent dislocations, progressive kyphoscoliosis, early osteoarthritis risk, motor delay, and aortopathy that needs surveillance.
- **Prognostic factors:** truncating variants and hydrops point to severe disease. Some missense alleles, such as p.Trp125Cys, give a milder MED-like course.

## 12. Treatment

There is no disease-modifying therapy, no pharmacogenomics and no clinical trials; I found no NCT registrations for DBQD. Management is supportive and multidisciplinary.

| Intervention | Suggested NCIT term (verify) | `therapeutic_modality` |
|---|---|---|
| Respiratory support / ventilation in neonates | NCIT:C15747 Supportive Care (or a ventilation procedure term) | OTHER |
| Orthopaedic surgery (dislocation reduction, clubfoot, spinal fusion for kyphoscoliosis) | NCIT:C16186 Orthopedic Surgical Procedure | SURGERY |
| Physical therapy / rehabilitation | NCIT:C15302 Physical Therapy | BEHAVIORAL |
| Cleft palate repair | NCIT:C15329 Surgical Procedure | SURGERY |
| Cardiology surveillance (echocardiography) for MVP and aortic dilatation; cardiac surgery if needed | — | — |
| Genetic counselling | NCIT:C15240 Genetic Counseling | — |

**Experimental approaches:** only preclinical ideas exist, for example bypassing the GAG defect. Nothing is in trials.

## 13. Prevention

- **Primary prevention:** not applicable.
- **Secondary prevention:** carrier testing, prenatal diagnosis by ultrasound plus *CANT1* testing, and PGT-M for at-risk couples (Forster 2019; Özalp 2025).
- **Tertiary prevention:**
  - spinal and joint surveillance;
  - echocardiographic monitoring of the aortic root and mitral valve (Öztürk 2025 recommends early cardiovascular follow-up);
  - anaesthetic airway planning.
- **Genetic counselling:** 25% recurrence risk per pregnancy.

## 14. Other species and natural disease

I found no naturally occurring CANT1 disease in OMIA (not exhaustively searched). Orthologues are mouse *Cant1* and zebrafish *cant1a/b*; get NCBI Gene IDs by lookup rather than from memory. CANT1 is conserved across vertebrates.

## 15. Model organisms

| Model | Phenotype recapitulation | Limitations | Source |
|---|---|---|---|
| *Cant1* knock-out and knock-in mice (Paganini 2019, Matrix Biol) | **Recapitulates** human DBQD1: skeletal undergrowth, reduced GAG synthesis, shorter chains, increased sulfation, delayed proteoglycan secretion, dilated ER, disturbed growth-plate proliferation and maturation | No canonical ER stress, so the mechanism of ER dilation is unclear | PMID:30439444 (MODEL_ORGANISM / IN_VITRO) |
| CRISPR *Cant1* KO mice (Kodama 2020) | Dwarfism, thoracic kyphosis, delta phalanx; reduced growth-plate GAG; impaired hypertrophic differentiation | — | PMID:32277574 |
| Same mouse line, aggrecan/decorin analysis | Shorter GAG chains on cartilage aggrecan and on skin decorin; proteoglycans are still glycanated | Effect on ECM distribution is moderate | PMID:39334831 |
| *Cant1*−/− tendon study | Tendon hypoplasia; less DS/CS; larger, angular collagen fibrils; tenocyte proliferation normal | Link to human joint laxity is inferred | PMID:40141107 |
| Patient fibroblasts (in vitro) | Reduced GAG synthesis under β-D-xyloside | Not chondrocytes | PMID:22539336 |
| Heterologous expression of mutant CANT1 | Loss of activity, dimerization and secretion | Cell-free/overexpression | PMID:21037275, PMID:32907608 |

---

## Key references

- Huber C et al. 2009. *Am J Hum Genet.* PMID:19853239. The gene discovery paper.
- Faden M et al. 2010. PMID:20425819.
- Furuichi T et al. 2011. PMID:21037275. Type 2 and Kim variant; loss-of-function functional data.
- Dai J et al. 2011. PMID:21412251. East Asian founder variant.
- Laccone F et al. 2011. *Eur J Hum Genet.* PMID:21654728. Fetal hydrops.
- Nizon M et al. 2012. *Hum Mutat.* PMID:22539336. Phenotypic spectrum; GAG synthesis in fibroblasts.
- Singh A et al. 2015. PMID:25486376.
- Paganini C et al. 2019. *Matrix Biol.* PMID:30439444. Knock-out and knock-in mouse models.
- Forster KR et al. 2019. PMID:31587486.
- Kodama K et al. 2020. *FEBS Open Bio.* PMID:32277574.
- Wang HD et al. 2020. PMID:32907608.
- Kuang L et al. 2020. PMID:32922611.
- Thomas MM et al. 2021. PMID:34602954.
- Biji IK et al. 2023. PMID:36331722.
- Piwar H et al. 2024. *Int J Mol Sci.* PMID:39273648. Review of 111 published cases.
- Gramegna Tota C et al. 2024. PMID:39334831.
- Yamashita R et al. 2025. PMID:40141107.
- Öztürk M et al. 2025. *Eur J Pediatr.* PMID:40461715. Cardiovascular cohort.
- Daşar T et al. 2025. PMID:39618316.
- Özalp M et al. 2025. PMID:40368527.
- Tsujioka Y et al. 2026. PMID:42094029. Review of GAG biosynthesis disorders.

**Web sources:** [PMC2775828](https://pmc.ncbi.nlm.nih.gov/articles/PMC2775828), [PMC3427906](https://pmc.ncbi.nlm.nih.gov/articles/PMC3427906), [PMC6598859](https://pmc.ncbi.nlm.nih.gov/articles/PMC6598859), [PMC7476945](https://pmc.ncbi.nlm.nih.gov/articles/PMC7476945), [PMC8436611](https://pmc.ncbi.nlm.nih.gov/articles/PMC8436611), [PubMed 30439444](https://pubmed.ncbi.nlm.nih.gov/30439444/), [MedGen C4012146](https://ncbi.nlm.nih.gov/medgen/C4012146), [MalaCards](https://www.malacards.org/card/desbuquois_dysplasia_1), [Imagine Institute](https://www.institutimagine.org/fr/identification-cant1-mutations-desbuquois-dysplasia-938).

## Curation caveats

- **Entry overlap:** `kb/disorders/Desbuquois_Dysplasia_1.yaml` already exists as an 8-line skeleton. There is also a lumped stub, `stubs/Desbuquois_Dysplasia.yaml` (MONDO:0015426), arguing that DBQD1 and DBQD2 should be one entry. Settle that lump-or-split question before populating the file.
- **Terms:** every HPO, GO, UBERON and NCIT CURIE above was suggested from memory. Each must be looked up before binding.
- **Gene validity:** ClinGen's Definitive AR assertion for this exact MONDO term can be recorded directly in `gene_disease_validity` with the CGGV identifier given in section 1.

## Reference Validation

Checked with `linkml-reference-validator` 0.5.1.

| Outcome | Count |
| --- | --- |
| References checked | 26 |
| Resolved | 26 |
| Unresolved (possible confabulation) | 0 |
| Unverifiable | 0 |
| Quoted claims checked | 2 |
| Quoted claims found in source | 2 |
| Quoted claims **not** found in source | 0 |
| References weighed for topical relevance | 26 |
| On topic | 20 |
| Off topic | 0 |

All extracted references resolved successfully.

## Term Validation

Checked with `linkml-term-validator` 0.4.5, through the `ols:` adapter.

| Outcome | Count |
| --- | --- |
| Terms checked | 71 |
| Resolved | 67 |
| Unresolved (possible confabulation) | 1 |
| Obsolete | 1 |
| Unverifiable | 2 |
| Terms whose name was checked | 9 |
| Terms named correctly | 4 |
| Terms named as a **different** term | 1 |
| Terms whose name is worth a second look | 4 |

### Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

- `UBERON:0003672` (1 mention) - the report calls it "verify"; UBERON calls it **dentition**

### Unresolved terms

These identifiers do not exist in an ontology that resolved other terms from the same prefix, so they were most likely invented:

- `HP:0009619` (1 mention) - HP does not contain this term

### Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

- `GO:0030206` (obsolete chondroitin sulfate biosynthetic process) (1 mention) - replaced by `GO:0050650`

### Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a *related* synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

- `MONDO:0015426` (2 mentions) - the report calls it "stubs/Desbuquois_Dysplasia.yaml"; MONDO calls it **Desbuquois dysplasia**
- `HP:0001631` (1 mention) - the report calls it "Atrial septal defect (small)"; HP calls it **Atrial septal defect**
- `HP:0001263` (1 mention) - the report calls it "Developmental delay (usually motor, secondary to joint problems)"; HP calls it **Global developmental delay**, and lists "Developmental delay in early childhood" among its other names
- `HP:0002654` (1 mention) - the report calls it "Multiple epiphyseal dysplasia-like presentation (mild end)"; HP calls it **Multiple epiphyseal dysplasia**

### Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: `OMIM`, `ORPHA`.